Trending...
- Assymetrix Launches the Deepest Independent Prediction Market Data API
- "I'm Sicka Church Too: Give Me Kingdom!" Ignites a Powerful Call for Healing and Truth
- Brian Keenan Joins ALLY Construction Services as Director of Business Development
WEXFORD, Pa., Oct. 24, 2024 ~ Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) has recently announced an expansion of its license agreement with Deverra Therapeutics Inc. This move will allow Coeptis to broaden the potential applications of its allogeneic natural killer (NK) cell technology in the treatment of viral infections, pandemic-related illnesses, and emergency stockpiling for future health crises.
The agreement, which was initially secured in August 2023, granted Coeptis exclusive rights to key assets from Deverra including an allogeneic stem cell expansion and directed differentiation platform, two investigational new drug (IND) applications, and two Phase 1 clinical trial stage assets investigating DVX201 as an unmodified NK cell therapy generated from pooled donor CD34+ cells. These assets align with Coeptis' mission to develop treatments for targeting cancer, autoimmune and infectious diseases.
With this revised agreement, Coeptis will now have the ability to expand its field of use in the event of pandemic-related and emergency situations. This includes utilizing unmodified NK cells as a treatment for illnesses and injuries arising from a pandemic or act of terror or war, such as Acute Radiation Sickness (ARS). It also allows for the production and storage of unmodified NK cells in advance to prepare for future health crises.
More on The PennZone
Dave Mehalick, President and CEO of Coeptis Therapeutics expressed his excitement about this expansion stating that it "broadens the applicability of NK cells to ensure that we are prepared for future health crises and potentially address long term side effects that may arise as a result of a pandemic."
Coeptis Therapeutics Holdings, Inc., along with its subsidiaries including Coeptis Therapeutics, Inc. and Coeptis Pharmaceuticals, Inc., is a biopharmaceutical company focused on developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases. Their goal is to disrupt conventional treatment paradigms and improve patient outcomes. The company's product portfolio includes assets licensed from Deverra Therapeutics, an allogeneic cellular immunotherapy platform, and DVX201, a clinical-stage unmodified natural killer cell therapy technology. They are also developing a universal, multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR) and the GEAR cell therapy and companion diagnostic platforms in collaboration with VyGen-Bio and leading medical researchers at the Karolinska Institutet.
More on The PennZone
Coeptis' business model is centered around maximizing the value of its current product portfolio and rights through in-license agreements, out-license agreements, co-development relationships, and strategic partnerships. Their focus is on expanding their product rights and offerings, particularly in the areas of cancer and infectious diseases. The company is headquartered in Wexford, PA.
It is important to note that this news release contains forward-looking statements that involve risks and uncertainties. These statements are based on current expectations, forecasts, and assumptions that may cause actual results to differ materially from those projected. Coeptis urges readers to carefully review all cautionary statements regarding these forward-looking statements before making any investment decisions.
For more information on Coeptis Therapeutics Holdings, Inc., please visit their website at https://coeptistx.com/.
The agreement, which was initially secured in August 2023, granted Coeptis exclusive rights to key assets from Deverra including an allogeneic stem cell expansion and directed differentiation platform, two investigational new drug (IND) applications, and two Phase 1 clinical trial stage assets investigating DVX201 as an unmodified NK cell therapy generated from pooled donor CD34+ cells. These assets align with Coeptis' mission to develop treatments for targeting cancer, autoimmune and infectious diseases.
With this revised agreement, Coeptis will now have the ability to expand its field of use in the event of pandemic-related and emergency situations. This includes utilizing unmodified NK cells as a treatment for illnesses and injuries arising from a pandemic or act of terror or war, such as Acute Radiation Sickness (ARS). It also allows for the production and storage of unmodified NK cells in advance to prepare for future health crises.
More on The PennZone
- VeneerVibe Releases 2026 Snap-On Veneers Market Report
- David Cavanagh Launches AI SEO Company For ChatGPT And AI Search Visibility
- Matthew Cossolotto Spotlights Make a Promise Day 2026 Events, Including Official Launch of Harness Your PromisePower and Issuing a "Peace Promise"
- Landmark Expands Services to Include Specialized Glass and Glazing Solutions Across Los Angeles
- As Pentagon Releases Ufo Files, Debut Ya Novel Predicted It All
Dave Mehalick, President and CEO of Coeptis Therapeutics expressed his excitement about this expansion stating that it "broadens the applicability of NK cells to ensure that we are prepared for future health crises and potentially address long term side effects that may arise as a result of a pandemic."
Coeptis Therapeutics Holdings, Inc., along with its subsidiaries including Coeptis Therapeutics, Inc. and Coeptis Pharmaceuticals, Inc., is a biopharmaceutical company focused on developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases. Their goal is to disrupt conventional treatment paradigms and improve patient outcomes. The company's product portfolio includes assets licensed from Deverra Therapeutics, an allogeneic cellular immunotherapy platform, and DVX201, a clinical-stage unmodified natural killer cell therapy technology. They are also developing a universal, multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR) and the GEAR cell therapy and companion diagnostic platforms in collaboration with VyGen-Bio and leading medical researchers at the Karolinska Institutet.
More on The PennZone
- RAATV Premieres Original Reality Series "The Access Index: Jackson" June, 19
- Connecticut Resident Develops Patent-Pending Concept Exploring a New Approach to GPS Navigation
- JP Events Azerbaijan to Host 2nd Women in Motorsport Event During the Azerbaijan Grand Prix Week
- MMA Platform Makes History, Pays Jamey-Lyn Horth After Fans Vote on UFC Winnipeg Robbery
- Resident Inspect Joins Property Meld Nexus Network with API Integration
Coeptis' business model is centered around maximizing the value of its current product portfolio and rights through in-license agreements, out-license agreements, co-development relationships, and strategic partnerships. Their focus is on expanding their product rights and offerings, particularly in the areas of cancer and infectious diseases. The company is headquartered in Wexford, PA.
It is important to note that this news release contains forward-looking statements that involve risks and uncertainties. These statements are based on current expectations, forecasts, and assumptions that may cause actual results to differ materially from those projected. Coeptis urges readers to carefully review all cautionary statements regarding these forward-looking statements before making any investment decisions.
For more information on Coeptis Therapeutics Holdings, Inc., please visit their website at https://coeptistx.com/.
Filed Under: Business
0 Comments
Latest on The PennZone
- I Voted Tvocracy and I Voted Radiocracy
- Tolle Lege Learning Launches Publishing House to Revolutionize Early Learning Initiatives
- HRC Fertility Celebrates Beverly Hills Grand Opening, Spotlighting Fertility Care as Women's Health Month Begins
- HRC Fertility's Dr. Christo G. Zouves Appointed to San Mateo County Medical Association Board of Directors
- HealthBook+ and Stonebrook Risk Solutions Partner to Bring Predictive Intelligence to Healthcare Risk
- Umbrella Becomes First FinOps Platform to Support AWS Billing Transfer Onboarding
- RECYCLEXPERT FZE Strengthens Leadership in Data Destruction UAE and GCC with Certified Secure ITAD Services
- Plasma-Activated Nitric Oxide Cream Outperforms L-Arginine Skincare - New Research Explains Why
- Assymetrix Launches the Deepest Independent Prediction Market Data API
- CCHR: 'Plant-Based' Psychedelics Push Masks Synthetic Drugs and Billion-Dollar Profits
- BTR: i2 Group Launches i2 Amplify, a Community Platform for Intelligence Professionals Worldwide
- L.A. Watts Summer Games Announces Free Pelé Tribute Event at Magic Johnson Park
- SUMOFIBER Fuels Explosive Growth With netElastic vBNG
- Brian Keenan Joins ALLY Construction Services as Director of Business Development
- Burkentine Builders Recognizes Local Fire Departments As Part Of Their Live With Purpose Initiative
- God's Meal Barrel Raises $3,135 During Give Local York
- NRx Pharmaceuticals (N A S D A Q: NRXP) Accelerates Into National Spotlight as Manufacturing Launch, Federal Policy & AI-Driven Breakthroughs Converge
- Expanding Into High-Margin Battery Recycling With Black Mass Strategy plus Scaling AI Infrastructure & Global Supply Chain Platform: N A S D A Q: MWYN
- Long-Distance Couples Spend Nearly $7,000 on Travel Before Moving In Together, New Mayflower Research Finds
- Pittsburgh Author Embraces Wisdom in The Principal Thing